Latest Headlines

Latest Headlines

Roche looks ahead to immuno-oncology, MS to back up big-selling cancer meds

Roche counts on its tried-and-true cancer drugs Rituxan, Avastin and Herceptin to bring home the bacon, and the meds did not disappoint in 2015. But despite the drugs' strong performance, Roche still missed on profits last year, disheartening news for the company as it readies itself for biosimilar competition to some of its top sellers.

Old standbys deliver for Roche in Q3 while Esbriet, Perjeta come on strong

Roche's bread-and-butter cancer drugs--Rituxan, Avastin and Herceptin--delivered once again in the third quarter, and now the Swiss drugmaker expects 2015 to turn out better than it previously had forecast.

Roche says fake MabThera has surfaced in EU

Roche is again tracking down counterfeits of some of its cancer meds in Europe after an importer in Germany discovered the fakes. In this case, it is counterfeit MabThera, sold as Rituxan in the U.S.

Top 10 best-selling cancer drugs of 2013

When it comes to selling big, cancer drugs have a lot going for them. Their targets--deadly diseases that in many cases can kill quickly--put them in high demand, even as they continue to redefine...

Roche gets thumbs up for CLL use of Gazyvaro in EU

Gazyva, Roche's successor to Rituxan, is already approved in the U.S. for first-line use on chronic lymphocytic leukemia (CLL) and appears poised for the same in Europe. The EU Committee for Medicinal Products for Human Use (CHMP) today recommended it for approval there.

Roche nabs European approval for time-saving formulation of Rituxan

Pharma companies sometimes try to extend the lives of drugs by developing new formulations or follow-on products before their patent expires. Swiss pharma giant Roche scored a victory today when European regulators approved a subcutaneous version of its cancer drug Rituxan, known as MabThera overseas.

The 10 best-selling drugs of 2013

It is the big sellers, the blockbusters--no, megablockbusters--that drug execs aspire to develop. And a look at the top 10 best-selling drugs globally can't help but impress with its big numbers.

Roche's new Gazyva beats predecessor Rituxan at staving off CLL

With new trial data, Roche has more support for its thesis that Rituxan successor Gazyva beats the original. Combined with the chemo drug chlorambucil, Gazyva helped patients live a median of 26.7 months without their cancer progressing, compared with 15.2 months for the Rituxan-plus-chlorambucil combination.

Roche's Rituxan successor first up in market scramble for first-line treatment of CLL

A number of drugmakers have been looking to get drugs across the finish line for approval of first-line use in the treatment of chronic lymphocytic leukemia, and Roche's Genentech and Biogen Idec have gotten there first. The FDA today approved their drug Gazyva, a successor to Roche's Rituxan that it hopes will offset some of massive sales that drug generates when it finally succumbs to biosimilar competition.

Oncobiologics allies with inVentiv on biosimilars development

The Cranbury, NJ-based biotech says they will focus on knockoffs of Humira, Rituxan, Avastin, Herceptin and Erbitux.